Pfizer (PFE)
Johnson & Johnson (JNJ)
Inc., and Elan Corp. ended most plans to develop an Alzheimer’s drug after a second trial failure, a blow to the companies’ efforts to market the first product to slow progress of the disease.
Bapineuzumab, designed to attack the brain plaques that serve as a hallmark of Alzheimer’s, failed to improve symptoms of dementia in the second of four final-stage trials of the drug, Pfizer and J&J said yesterday in statements. Elan’s American depositary receipts fell 11 percent to $10.02 at 9:44 a.m. New York time.
Read the full story: http://tinyurl.com/9lst2tr
Source: Bloomberg
FDA Approves Nirogacestat for Treatment of Desmoid Tumors
November 28th 2023Desmoid tumors are noncancerous growths that appear in connective tissue, most often on the arms, legs, and abdomen. Aggressive tumors must be treated with surgery, radiation, or chemotherapy to keep them from growing into nearby organs, which can make them life-threatening. They can cause pain and disfigurement, and they can reduce functioning and quality of life.
Read More
Managed Care Cast Presents: Opportunities for Adalimumab Biosimilars, Part 1
November 10th 2023In part 1 of this 2-part podcast, a panel of experts discusses the provider and payer considerations for transitioning patients to biosimilars, approaches to prescribing biosimilars over reference products, and more.
Listen
Lawsuits target initiatives aimed at reducing racial disparities; less than 10% of trials for COVID-19 treatments included children in the first 3 years of the pandemic; the World Health Organization requests more information on increased respiratory illnesses in China.
Read More
2 Clarke Drive
Cranbury, NJ 08512